-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

A new radiotracer developed at the University of Alberta and soon to be tested in human clinical trials in Europe could make ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

The study, published Tuesday in The Lancet Oncology, focused on women under 55 with and without a uterus. CBS News medical ...

Cambridge UK Pharma giant AstraZeneca is proving a variation on the proverbial enigma as it ponders the most appreciative ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

With AstraZeneca reported to be looking into moving its listing across the Atlantic, should investors buy the stock ahead of ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

Breast cancer treatment might offer protection against Alzheimer's disease, with a study of 70,000 survivors showing lower ...